Peter Barton Hutt, former Chief Counsel at the FDA and pioneer of medical device regulatory policy, joins as Plan A™ concludes successful trials. Los Angeles, CA – August 27, 2025 – NEXT Life Sciences, the modern reproductive healthcare company pioneering Plan A™, a first-of-its-kind, long-lasting, and on-demand-reversible male contraceptive, announced today the addition of renowned FDA […]| TechBullion
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
The FDA has approved Benlysta in an autoinjector that can be used at home to treat lupus nephritis, a kidney complication, in children.| Lupus News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't controlled.| COPD News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
UPSIDE Foods announces it has received a No Questions Letter from the US FDA for its cultivated chicken,| vegconomist - the vegan business magazine
In the first part of a two-part series, Ann Harrison interviews addiction treatment expert Dr. Howard Kornfeld about the FDA decision to reject the Lykos Therapeutics proposal for MDMA-assisted therapy.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Prior to last week's FDA decision to reject Lykos Therapeutics' proposed MDMA-assisted therapy for PTSD, Rep. Jack Bergman (R-MI) reflected on the urgent need for better PTSD treatments to reduce veteran suicides and the game plan for lawmakers to keep support for psychedelic-assisted therapies moving forward.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics awaits an FDA decision this week on its proposed MDMA-assisted therapy for PTSD, the company has announced new initiatives and measures for additional oversight if the therapy is approved.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
